Hints and tips:
...Lee, the grandson of Samsung founder Lee Byung-chul, is also accused of orchestrating a $3.9bn accounting fraud at the group’s biopharmaceutical unit in 2015 as part of the same case....
...In December, biopharmaceutical firm Amgen announced the acquisition of biotech star Horizon Therapeutics for $116.50 per share or $28bn in aggregate....
...Gorsky said the separation would allow J&J to focus on “delivering industry-leading biopharmaceutical and medical device innovation and technology”, while the new consumer health company would be “a global...
...Angela Hwang, president of Pfizer Biopharmaceuticals Group, said available data supported a booster programme to protect the public and help bring an end to the pandemic sooner rather than later....
...South Korean biopharmaceuticals group Celltrion is betting that new variants of Covid-19 will fuel growth in the US and Europe for treatments of the disease, even as these markets vaccinate their populations...
...Mene Pangalos, executive vice-president for biopharmaceuticals at AstraZeneca, said: “We have an effective vaccine that meets regulatory requirements for approval around the world.”...
...Vamil Divan, senior biopharmaceuticals research analyst at Mizuho, said it looked unlikely that Pfizer would publish this data until next week or later....
...With all this in the background, local conglomerate SK Group’s biopharmaceuticals division goes public on Thursday, with perfect timing....
...Angela Hwang, president of Pfizer’s biopharmaceuticals group, said the company would use the same principles to price the vaccine in developed countries....
...A version of this article was first published by Nikkei Asia on December 15, 2020. ©2020 Nikkei Inc. All rights reserved....
...The Big Story China Inc is paying heavily for associations with Beijing’s “surveillance state”....
...Kenneth Frazier, Merck’s chief executive, said the move would bring Merck closer to being “the premier research-intensive biopharmaceutical company”, while allowing the new company to focus on products that...
...US pharmaceutical company Merck has agreed a $1.05bn cash deal to buy Peloton Therapeutics, gaining access to the biopharmaceutical company’s renal cancer drug treatment that is in development....
...Even before striking the deal for Allergan, AbbVie had spent $21bn on biopharmaceutical company Pharmacyclics in 2015 in a bid to bolster its drug pipeline....
...Pfizer’s biopharmaceuticals unit Upjohn reported 25 per cent growth year-on-year in emerging markets, driven by sales of the statin Lipitor, Norvasc for angina and the arthritis treatment Celebrix in China...
...Five employees from Samsung Electronics and three from the group’s biopharmaceutical affiliates Samsung BioLogics and Samsung Bioepis have been arrested in recent months....
...The changes, which created two units — one focused on oncology and another for biopharmaceuticals — were intended to streamline the process from initial discovery through to late-stage development and marketing...
...The company has been executing its strategy to drive growth and value for shareholders as it transforms into a global biopharmaceutical leader....
...However, a separate investigation into rival Celltrion Healthcare renewed concerns over opaque accounting practices in the country’s biopharmaceutical sector....
...He added: “The most fundamental way the biopharmaceutical industry creates value is by discovering innovative medicines that help people live longer, healthier, more productive lives.”...
...“The most fundamental way the biopharmaceutical industry creates value is by discovering innovative medicines that help people live longer, healthier, more productive lives.”...
...Our board and management are committed to creating a world class biopharmaceutical and aesthetics business and driving shareholder returns....
...A version of this article was first published by the Nikkei Asian Review on July 11, 2018. ©2018 Nikkei Inc. All rights reserved....
...Celltrion has become the darling of global investors, leading the biopharmaceutical rally in South Korea with its stock price doubling last year....
...Carol Lynch, global head of biopharmaceuticals at Sandoz, said that between 2017 and 2020 the company will launch five biosimilars, mostly in immunology and oncology....
International Edition